Epirus Biopharmaceuticals (NASDAQ: EPRS) and Soligenix (NASDAQ:SNGX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Insider & Institutional Ownership

2.0% of Soligenix shares are held by institutional investors. 5.0% of Soligenix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Epirus Biopharmaceuticals and Soligenix’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Epirus Biopharmaceuticals N/A N/A N/A ($2.53) -0.06
Soligenix $6.98 million 1.89 -$6.76 million ($1.36) -1.70

Epirus Biopharmaceuticals has higher revenue, but lower earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Epirus Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Epirus Biopharmaceuticals has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 2.25, meaning that its share price is 125% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Epirus Biopharmaceuticals and Soligenix, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Epirus Biopharmaceuticals 0 0 0 0 N/A
Soligenix 0 0 2 0 3.00

Soligenix has a consensus price target of $8.00, indicating a potential upside of 246.32%. Given Soligenix’s higher probable upside, analysts plainly believe Soligenix is more favorable than Epirus Biopharmaceuticals.

Profitability

This table compares Epirus Biopharmaceuticals and Soligenix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Epirus Biopharmaceuticals -2,025.65% -208.66% -97.67%
Soligenix -86.15% -129.88% -74.33%

Summary

Soligenix beats Epirus Biopharmaceuticals on 9 of the 10 factors compared between the two stocks.

About Epirus Biopharmaceuticals

EPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company’s products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.

About Soligenix

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

Receive News & Ratings for Epirus Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epirus Biopharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.